Your Best Stock

Moderna MRNA

US equityMarket cap rank #226Infectious Disease
$185.08
+$2.97 (+1.63%)
Market open · Sep 24, 2:00 pm ET
After hours $181.30 -0.44%
Open$180.60
Prev close$182.11
Day range$180.39 – $189.22
Volume8.88M
Market cap$73.89B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±6.1%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+13.5%
Worst reaction-21.0%

Stock move on the day after each report

-6.5%2023/Q3+13.5%2023/Q4+12.7%2024/Q1-21.0%2024/Q2-3.0%2024/Q3+3.4%2024/Q4-5.3%2025/Q1-6.6%2025/Q2+3.3%2025/Q3+5.3%2025/Q4-1.2%2026/Q1-5.4%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q231 Jul 2026Pre Market±6.5%-5.35%Within range
2026/Q11 May 2026Pre Market±5.0%-1.24%Within range
2025/Q413 Feb 2026Pre Market±4.7%+5.29%Bigger than priced
2025/Q36 Nov 2025Pre Market±1.9%+3.27%Bigger than priced
2025/Q21 Aug 2025Pre Market±3.6%-6.61%Bigger than priced
2025/Q11 May 2025Pre Market±3.1%-5.29%Bigger than priced
2024/Q414 Feb 2025Pre Market±4.0%+3.35%Within range
2024/Q37 Nov 2024Pre Market±7.0%-2.95%Within range
2024/Q21 Aug 2024Pre Market±9.8%-21.01%Bigger than priced
2024/Q12 May 2024Pre Market±8.5%+12.68%Bigger than priced
2023/Q422 Feb 2024–±8.6%+13.53%Bigger than priced
2023/Q32 Nov 2023Pre Market±6.4%-6.52%Bigger than priced
2023/Q23 Aug 2023–±8.3%-0.25%Within range
2023/Q14 May 2023–±9.1%+3.22%Within range
2022/Q423 Feb 2023–±11.5%-6.70%Within range
2022/Q33 Nov 2022–±12.5%-0.75%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • COVID$91.00M 62.8%
  • Other revenue$51.00M 35.2%
  • Respiratory syncytial virus (RSV)$3.00M 2.1%

Latest reported quarter: Q2, ended Jun 2026

Revenue$143.00M+4.4% YoY
Operating profit-$815.00M+10.1% YoY
Net profit-$782.00M+5.2% YoY
Diluted EPS-$1.97+7.5% YoY
Free cash flow-$563.00M+38.9% YoY
Operating cash flow-$526.00M

Revenue, last 8 quarters

$1.9BSep '24$956.0MDec '24$107.0MMar '25$137.0MJun '25$1.0BSep '25$676.0MDec '25$389.0MMar '26$143.0MJun '26

Net profit, last 8 quarters

$13.0MSep '24$-1.1BDec '24$-971.0MMar '25$-825.0MJun '25$-200.0MSep '25$-826.0MDec '25$-1.3BMar '26$-782.0MJun '26

Profitability & balance sheet

Gross margin22.8%
Operating margin-150.2%
Net margin-142.6%
Return on equity-39.0%
Return on assets-27.4%
Return on invested capital-36.2%
Current ratio2.29
Liabilities / assets38.3%
Cash & investments$5.14B
Total debt$1.24B
Net cash (debt)$3.90B
Scroll to Top